First IL-17A biologic approved for polymyalgia rheumatica
MDSpire News
November 17, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

The FDA approved secukinumab 150 mg as the first IL-17A inhibitor for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering.
In the 381-participant REPLENISH trial, sustained remission at week 52 occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.
Mean adjusted cumulative glucocorticoid dose through week 52 was 1,683.2 mg with secukinumab and 2,093 mg with placebo.
Median time to rescue treatment for a polymyalgia rheumatica flare was 282 days with secukinumab and 157 days with placebo.
The prescribing information warns of serious infections and inflammatory bowel disease and recommends tuberculosis evaluation and age-appropriate vaccinations before treatment.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: